CAMBRIDGE, Mass., Nov. 14 /PRNewswire-FirstCall/ -- ViaCell, Inc. today announced that its common stock was selected to be added to the NASDAQ Biotechnology Index(R) (NBI) effective at the beginning of trading on Monday, November 21, 2005.
All securities in the Index are classified according to the FTSE(TM) Global Classification System as either biotechnology or pharmaceutical, listed on the Nasdaq National Market and meet minimum requirements, including market value and average daily share volume, among other criteria. The Index is ranked on a semi-annual basis in May and November.
ViaCell is a biotechnology company focused on enabling the widespread use of human cells as medicine. The Company is developing a pipeline of proprietary stem cell product candidates intended to address cancer, cardiac disease, and diabetes. CB001, its lead cord blood derived stem cell therapy product candidate, is being developed for hematopoietic stem cell transplantation in patients affected by a variety of cancers. In addition to its therapeutic development programs, ViaCell's reproductive health business unit commercializes ViaCord(R), a product that offers expecting families the option of preserving their baby's umbilical cord blood. The Company is working to leverage its commercial infrastructure and product development capabilities by developing ViaCyte(TM), its investigational product intended to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell is headquartered in Cambridge, Massachusetts with a processing and storage facility in Kentucky and additional research and development operations in Singapore.
ViaCell(R) and ViaCord(R) are registered trademarks and ViaCyte(TM) is a trademark of ViaCell, Inc. All other trademarks are those of the respective owners.
For Additional Information Contact: Justine E. Koenigsberg Senior Director, Corporate Communications (617) 914-3494
ViaCell, Inc.CONTACT: Justine E. Koenigsberg, Senior Director, CorporateCommunications, ViaCell, Inc., +1-617-914-3494
Web site: http://www.viacord.com/
